Enhabit (EHAB) Proxy Filing summary
Event summary combining transcript, slides, and related documents.
Proxy Filing summary
23 Feb, 2026Executive summary
Agreement reached for acquisition by Kinderhook Industries, a private investment firm focused on healthcare services.
Transaction expected to close in the second quarter of 2026, after which the company will become privately held and delist from the NYSE.
Anticipated benefits include access to additional resources, expertise, and long-term investment flexibility.
Forward-looking statements highlight potential risks, including transaction completion, regulatory approvals, and business disruptions.
Voting matters and shareholder proposals
A special meeting of stockholders will be called to obtain approval for the proposed acquisition.
Proxy materials, including a definitive proxy statement, will be filed and made available to investors.
Board of directors and corporate governance
Directors and executive officers may be considered participants in the proxy solicitation for the transaction.
Information about directors and officers is available in the company's 2025 annual meeting proxy statement.
Latest events from Enhabit
- Pending merger with Kinderhook Industries follows a year of revenue growth and operational improvement.EHAB
Proxy Filing5 Mar 2026 - Revenue and EBITDA rose, leverage fell, and a merger is pending.EHAB
Q4 20255 Mar 2026 - Acquisition by Kinderhook Industries prompts shareholder vote and transition to private ownership.EHAB
Proxy Filing26 Feb 2026 - Kinderhook Industries to acquire Enhabit; shareholders to receive $13.80 per share upon closing.EHAB
Proxy Filing23 Feb 2026 - Stockholders to receive $13.80 per share in a $1.1B buyout, pending approvals.EHAB
Proxy Filing23 Feb 2026 - Adjusted EBITDA rose 5.4% as non-Medicare admissions and hospice growth offset revenue softness.EHAB
Q2 20242 Feb 2026 - Growth driven by payer contract expansion, operational efficiency, and disciplined capital use.EHAB
Goldman Sachs 45th Annual Global Healthcare Conference1 Feb 2026 - Diversified contracts and operational gains drive growth despite Medicare headwinds.EHAB
2024 Wells Fargo Healthcare Conference22 Jan 2026 - Adjusted EBITDA up 5.6%, but goodwill impairment drove a $110.2M net loss; hospice grew 11%.EHAB
Q3 202416 Jan 2026